Re-engineering immune memory for tissue repair

Infinimmune has successfully secured a $75 million Series A financing round to propel its development of human-derived monoclonal antibodies towards clinical trials. The funding, co-led by Regeneron Ventures and Playground Global, includes contributions from notable investors such as RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Wild Tree Ventures, along with existing supporters like the Merck Global Health Innovation Fund and Everbright Biofund. The capital is intended to support first-in-human trials for the biotech company's two leading candidates in 2027, both of which focus on atopic dermatitis, with aspirations to expand into chronic inflammatory diseases more broadly.

Infinimmune, based in Alameda, California, utilizes its proprietary Anthrobody platform and Complete Human technology to engineer therapeutic antibodies specifically targeting autoimmune and inflammatory diseases. By tapping into the human immune system rather than relying on synthetic antibody libraries or animal models, the company screens single B cells from human donors. This approach, combined with advanced computational methods, seeks to deliver antibody therapeutics that boast enhanced safety profiles and clinical efficacy compared to traditional engineered antibodies.

Targeting atopic dermatitis is a strategic decision for Infinimmune, as the regulatory endpoints are well understood, and there is an established reimbursement pathway. The company’s choice also highlights the potential of its platform, which mines memory B cells to reveal insights into the molecular architecture of a well-functioning human immune repertoire. IL-13 and IL-22 are particularly relevant targets today, serving as proof that this discovery engine can accurately characterize immune function. This raises an intriguing question: what happens when this technology is applied to immune systems that are compromised due to aging rather than disease?

Inflammaging, characterized by chronic, low-grade immune dysregulation that worsens with age, presents a significant challenge in geroscience. While Infinimmune's platform was not explicitly designed to address this issue, it prompts speculation about future applications of their technology in understanding and potentially mitigating age-related immune decline.

The company’s pipeline currently includes two half-life extended monoclonal antibodies: IFX-101, targeting interleukin-22, and IFX-201, aimed at interleukin-13. These cytokines address different aspects of the inflammation associated with atopic dermatitis. Notably, IFX-101 would be the first biologic to target IL-22, a pathway that remains untapped by current therapies.

Dr. Emma Guttman, system chair of dermatology at the Icahn School of Medicine at Mount Sinai, remarked, “Ten years after the first systemic biologics received approval, achieving complete and durable disease control continues to be an elusive goal for many patients. IFX-101 targets IL-22, a pathway with no approved biologic, while IFX-201 delivers potentially best-in-class IL-13 neutralization and dosing convenience. Together, these programs offer the breadth to address complementary axes of disease and the opportunity to redefine what clear skin can mean for patients.”

Infinimmune's innovative approach to therapeutic antibody discovery contrasts sharply with the conventional reliance on immunizing transgenic mice or synthetic libraries. The company instead screens millions of individual human memory B cells across a multitude of targets. The human immune system’s ability to produce diverse structural iterations throughout a lifetime allows for the filtration of auto-reactive candidates and optimization of binding kinetics under real physiological conditions.

To analyze these single-cell sequencing datasets, Infinimmune employs its GLIMPSE generative protein language models for candidate selection and structural optimization. This computational layer identifies antibody sequences that are not only highly effective but also exhibit low immunogenicity and favorable developability profiles. Dr. Wyatt McDonnell, Cofounder and CEO of Infinimmune, stated, “The human immune system makes extraordinary antibodies. We built a company to find them and are uniquely positioned to turn them into transformative medicines for patients with unmet needs.”

The company's platform has already garnered significant commercial validation, including a multi-target discovery collaboration with Merck valued at up to approximately $838 million. Investors recognize the potential of combining computational modeling with human B cell screening to streamline discovery timelines while enhancing drug developability. Dr. Benjamin Kim, partner at Playground Global, noted, “Infinimmune’s Anthrobody platform produces antibodies with a combination of potency, half-life, and developability that we haven’t seen from conventional discovery approaches, and does so in a fraction of the time when compared to traditional technologies.”

As Infinimmune prepares for its initial human trials, the broader implications of its platform remain to be seen. Whether it can address conditions beyond dermatology is still an open question, particularly regarding the complexities of an aging immune system. The journey to transform human immune memory into effective therapies presents challenges, but it also holds the promise of addressing some of the most pressing health issues of our time.